20-hydroxyeicosatetraenoic acid inhibition attenuates balloon injury-induced neointima formation and vascular remodeling in rat carotid arteries

Journal of Pharmacology and Experimental Therapeutics

Volumn 346, Issue 1, 2013, Pages 67-74

  Orozco, Ludwig D ^a   Liu, Huiling ^a   Perkins, Eddie ^a,b   Johnson, Daryl A ^a   Chen, Betty B ^a   Fan, Fan ^a   Baker, Rodney C ^a   Roman, Richard J ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 AMINOBENZOTRIAZOLE; 20 HYDROXYICOSATETRAENOIC ACID; CYTOCHROME P450 4A; HET 0016; N HYDROXY N' [4 BUTYL 2 METHYLPHENYL]FORMAMIDINE; SMOOTH MUSCLE ACTIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY WALL; ARTICLE; BALLOON INJURY; BLOOD VESSEL INJURY; CAROTID ARTERIOGRAPHY; CAROTID ARTERY; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG INHIBITION; ENDOTHELIUM INJURY; FATTY ACID ANALYSIS; FATTY ACID BLOOD LEVEL; FATTY ACID SYNTHESIS; MALE; NEOINTIMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT; SMOOTH MUSCLE FIBER; TISSUE LEVEL; TREATMENT OUTCOME; VASCULAR REMODELING; VASCULAR SMOOTH MUSCLE; VASCULAR SURGERY;

ALKANE 1-MONOOXYGENASE; AMIDINES; ANGIOPLASTY, BALLOON, CORONARY; ANIMALS; CAROTID ARTERY INJURIES; CAROTID ARTERY, COMMON; CAROTID STENOSIS; CELL MOVEMENT; CELL PROLIFERATION; CYTOCHROME P-450 ENZYME SYSTEM; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; HYDROXYEICOSATETRAENOIC ACIDS; HYPERPLASIA; MALE; MUSCLE, SMOOTH, VASCULAR; NEOINTIMA; RATS; RATS, SPRAGUE-DAWLEY; TRIAZOLES; TUNICA INTIMA;

EID: 84879319684     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.113.203844     Document Type: Article

References (43)

1. Afergan E, Ben David M, Epstein H, Koroukhov N., Gilhar D, Rohekar K, Danenberg H.D., and Golomb G (2010) Liposomal simvastatin attenuates neointimal hyper-plasia in rats. AAPS J 12:181-187.
2. Balani SK, Zhu T, Yang T.J., Liu Z., He B, and Lee FW (2002) Effective dosing regimen of 1-aminobenzotriazole for inhibition of antipyrine clearance in rats, dogs, and monkeys. Drug Metab Dispos 30:1059-1062.
3. Bauters C and Isner JM (1997) The biology of restenosis. Prog Cardiovasc Dis 40: 107-116.
4. Bruijns RH, van Kleef EM, Smits JF, De Mey JG, and Daemen MJ (1998) Effects of chemical sympathectomy on angiotensin II-induced neointimal growth in the balloon-injured rat carotid artery. J Vasc Res 35:124-133.
5. Capdevila JH and Falck JR (2002) Biochemical and molecular properties of the cy-tochrome P450 arachidonic acid monooxygenases. Prostaglandins Other Lipid Mediat 68-69:325-344.
6. Chen L, Ackerman R, and Guo AM (2012) 20-HETE in neovascularization. Prosta-glandins Other Lipid Mediat 98:63-68.
7. Chen P, Guo M, Wygle D., Edwards PA, Falck JR, Roman RJ, and Scicli AG (2005) Inhibitors of cytochrome P450 4A suppress angiogenic responses. Am J Pathol 166: 615-624.
8. Davies MG and Hagen PO (1994) Pathobiology of intimal hyperplasia. Br J Surg 81: 1254-1269.
9. Ferguson GG, Eliasziw M, Barr H.W., Clagett GP, Barnes RW, Wallace MC, Taylor D.W., Haynes RB, Finan JW, and Hachinski VC, et al (1999) The North American Symptomatic Carotid Endarterectomy Trial: surgical results in 1415 patients. Stroke 30:1751-1758.
10. Fujita H, Saito F, Sawada T., Kushiro T, Yagi H, and Kanmatsuse K (1999) Lip-oxygenase inhibition decreases neointimal formation following vascular injury. Atherosclerosis 147:69-75.
11. Guo AM, Arbab AS, Falck J.R., Chen P., Edwards PA, Roman RJ, and Scicli AG (2007) Activation of vascular endothelial growth factor through reactive oxygen species mediates 20-hydroxyeicosatetraenoic acid-induced endothelial cell proliferation. J Pharmacol Exp Ther 321:18-27.
12. Hanke H, Strohschneider T, Oberhoff M., Betz E, and Karsch KR (1990) Time course of smooth muscle cell proliferation in the intima and media of arteries following experimental angioplasty. Circ Res 67:651-659.
13. Hill E and Murphy RC (1992) Quantitation of 20-hydroxy-5,8,11,14- eicosatetraenoic acid (20-HETE) produced by human polymorphonuclear leukocytes using electron capture ionization gas chromatography/mass spectrometry. Biol Mass Spectrom 21:249-253.
14. Hoagland KM, Flasch AK, and Roman RJ (2003) Inhibitors of 20-HETE formation promote salt-sensitive hypertension in rats. Hypertension 42:669-673.
15. Kissin I, Morgan PL, and Smith LR (1983) Comparison of isoflurane and halothane safety margins in rats. Anesthesiology 58:556-561.
16. Kundi R, Hollenbeck ST, Yamanouchi D, Herman B.C., Edlin R., Ryer EJ, Wang C, Tsai S, Liu B., and Kent KC (2009) Arterial gene transfer of the TGF-beta signalling protein Smad3 induces adaptive remodelling following angioplasty: a role for CTGF. Cardiovasc Res 84:326-335.
17. Liang CJ, Ives HE, Yang C.M., and Ma YH (2008) 20-HETE inhibits the proliferation of vascular smooth muscle cells via transforming growth factor-β. J Lipid Res 49: 66-73.
18. Lin F, Rios A, Falck J.R., Belosludtsev Y., and Schwartzman ML (1995) 20-Hydrox-yeicosatetraenoic acid is formed in response to EGF and is a mitogen in rat proximal tubule. Am J Physiol 269:F806-F816.
19. McGiff JC (1981) Prostaglandins, prostacyclin, and thromboxanes. Annu Rev Pharmacol Toxicol 21:479-509.
20. Miyata N and Roman RJ (2005) Role of 20-hydroxyeicosatetraenoic acid (20-HETE) in vascular system. J Smooth Muscle Res 41:175-193.
21. Miyata N, Taniguchi K, Seki T., Ishimoto T, Sato-Watanabe M, Yasuda Y, Doi M., Kametani S, Tomishima Y, and Ueki T, et al (2001) HET0016, a potent and selective inhibitor of 20-HETE synthesizing enzyme. Br J Pharmacol 133:325-329.
22. Muthalif MM, Benter IF, Karzoun N, Fatima S., Harper J, Uddin MR, and Malik KU (1998) 20-Hydroxyeicosatetraenoic acid mediates calcium/calmodulin- dependent protein kinase II-induced mitogen-activated protein kinase activation in vascular smooth muscle cells. Proc Natl Acad Sci USA 95:12701-12706.
23. Muthalif MM, Benter IF, Khandekar Z, Gaber L., Estes A, Malik S, Parmentier J.H., Manne V., and Malik KU (2000) Contribution of Ras GTPase/MAP kinase and cytochrome P450 metabolites to deoxycorticosterone-salt-induced hypertension. Hypertension 35:457-463.
24. Okamoto E, Couse T, De Leon H, Vinten-Johansen J, Goodman R.B., Scott NA, and Wilcox JN (2001) Perivascular inflammation after balloon angioplasty of porcine coronary arteries. Circulation 104:2228-2235.
25. Orozco LD, Liu H, Chen B.B., Fratkin JD, and Perkins E (2011) Angiographic evaluation of the rat carotid balloon injury model. Exp Mol Pathol 91:590-595.
26. Patricia MK, Kim JA, Harper C.M., Shih PT, Berliner JA, Natarajan R, Nadler J.L., and Hedrick CC (1999) Lipoxygenase products increase monocyte adhesion to human aortic endothelial cells. Arterioscler Thromb Vasc Biol 19:2615-2622.
27. Pietersma A, Kofflard M, de Wit LE, Stijnen T, Koster JF, Serruys P.W., and Sluiter W (1995) Late lumen loss after coronary angioplasty is associated with the activation status of circulating phagocytes before treatment. Circulation 91:1320-1325.
28. Reddy MA, Thimmalapura PR, Lanting L, Nadler J.L., Fatima S., and Natarajan R (2002) The oxidized lipid and lipoxygenase product 12(S)-hydroxyeicosatetraenoic acid induces hypertrophy and fibronectin transcription in vascular smooth muscle cells via p38 MAPK and cAMP response element-binding protein activation. Mediation of angiotensin II effects. J Biol Chem 277:9920-9928.
29. Reidy MA, Fingerle J, and Lindner V (1992) Factors controlling the development of arterial lesions after injury. Circulation 86(suppl)III43-III46.
30. Roman RJ (2002) P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev 82:131-185.
31. Sacerdoti D, Gatta A, and McGiff JC (2003) Role of cytochrome P450-dependent arachidonic acid metabolites in liver physiology and pathophysiology. [Review] Prostaglandins Other Lipid Mediat 72:51-71.
32. Samuelsson B (1983) Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science 220:568-575.
33. Sato M, Ishii T, Kobayashi-Matsunaga Y, Amada H., Taniguchi K, Miyata N, and Kameo K (2001) Discovery of a N'-hydroxyphenylformamidine derivative HET0016 as a potent and selective 20-HETE synthase inhibitor. Bioorg Med Chem Lett 11:2993-2995.
34. Seki Y, Kai H, Shibata R., Nagata T, Yasukawa H, Yoshimura A., and Imaizumi T (2000) Role of the JAK/STAT pathway in rat carotid artery remodeling after vascular injury. Circ Res 87:12-18.
35. Stec DE, Gannon KP, Beaird J.S., and Drummond HA (2007) 20-Hydroxyeicosate-traenoic acid (20-HETE) stimulates migration of vascular smooth muscle cells. Cell Physiol Biochem 19:121-128.
36. Stern N, Golub M, Nozawa K., Berger M, Knoll E, Yanagawa N., Natarajan R, Nadler JL, and Tuck ML (1989) Selective inhibition of angiotensin II-mediated vasoconstriction by lipoxygenase blockade. Am J Physiol 257:H434-H443.
37. Tulis DA (2007) Rat carotid artery balloon injury model. Methods Mol Med 139:1-30.
38. Uddin MR, Muthalif MM, Karzoun NA, Benter IF, and Malik KU (1998) Cytochrome P-450 metabolites mediate norepinephrine-induced mitogenic signaling. Hypertension 31:242-247.
39. Wu L, Zhu L, Shi W.H., Yu B., and Cai D (2011) Zoledronate inhibits intimal hyper-plasia in balloon-injured rat carotid artery. Eur J Vasc Endovasc Surg 41:288-293.
40. Xing D, Miller A, Novak L., Rocha R, Chen YF, and Oparil S (2004) Estradiol and progestins differentially modulate leukocyte infiltration after vascular injury. Circulation 109:234-241.
41. Xu F, Falck JR, Ortiz de Montellano PR, and Kroetz DL (2004) Catalytic activity and isoform-specific inhibition of rat cytochrome p450 4F enzymes. J Pharmacol Exp Ther 308:887-895.
42. Yaghini FA, Zhang C, Parmentier J.H., Estes AM, Jafari N, Schaefer SA, and Malik KU (2005) Contribution of arachidonic acid metabolites derived via cytochrome P4504A to angiotensin II-induced neointimal growth. Hypertension 45:1182-1187.
43. Zhao X and Imig JD (2003) Kidney CYP450 enzymes: biological actions beyond drug metabolism. Curr Drug Metab 4:73-84.